Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. [1]
Alexandra Sánchez stated that while multiple myeloma is incurable, new treatments have improved survival, with some patients now achieving 10 years or more of disease control compared to approximately five years a decade ago. [2] A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. [3] Novartis is conducting a thorough review of the observed safety events. [4]
The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. [5] Experts estimate that more than 2,200 people are diagnosed with multiple myeloma annually in Mexico, and over 1,300 die from the disease each year. [6] Kevin Nacho identified the development of CAR-T therapies, which use genetically modified T lymphocytes, as a major pending challenge for Mexico and Latin America. [7]
Kevin Nacho, medical manager of Hematology at GSK Mexico, stated that new targeted therapies and bispecific antibodies have changed the landscape of multiple myeloma treatment. [8]Novartis suspendió ocho ensayos clínicos de una terapia experimental dirigida a trastornos autoinmunes y neurológicos a finales de agosto, tras la muerte de tres pacientes. [1]
Alexandra Sánchez declaró que, si bien el mieloma múltiple es incurable, los nuevos tratamientos han mejorado la supervivencia, y algunos pacientes logran ahora 10 años o más de control de la enfermedad, en comparación con aproximadamente cinco años hace una década. [2] Un portavoz de Novartis indicó que los ensayos se suspendieron temporalmente tras el registro de graves respuestas inmunitarias en los tres casos. [3] Novartis está realizando una revisión exhaustiva de los eventos de seguridad observados. [4]
La empresa identificó la respuesta inmunitaria mortal como un riesgo de seguridad conocido en las terapias CAR-T, que modifican las células inmunitarias del paciente para reconocer y destruir células cancerosas. [5] Expertos estiman que más de 2.200 personas son diagnosticadas con mieloma múltiple anualmente en México, y más de 1.300 mueren por la enfermedad cada año. [6] Kevin Nacho identificó el desarrollo de las terapias CAR-T, que utilizan linfocitos T modificados genéticamente, como un importante desafío pendiente para México y América Latina. [7]
Kevin Nacho, gerente médico de Hematología en GSK México, declaró que las nuevas terapias dirigidas y los anticuerpos biespecíficos han cambiado el panorama del tratamiento del mieloma múltiple. [8]
Proof8 sources · 2 publishers
What this stands on
Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. · elpaisvallenato.com
Alexandra Sánchez stated that while multiple myeloma is incurable, new treatments have improved survival, with some patients now achieving 10 years or more of disease control compared to approximately five years a decade ago. · El Economista
A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. · elpaisvallenato.com
Novartis is conducting a thorough review of the observed safety events. · elpaisvallenato.com
The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. · elpaisvallenato.com
Experts estimate that more than 2,200 people are diagnosed with multiple myeloma annually in Mexico, and over 1,300 die from the disease each year. · El Economista
Kevin Nacho identified the development of CAR-T therapies, which use genetically modified T lymphocytes, as a major pending challenge for Mexico and Latin America. · El Economista
Kevin Nacho, medical manager of Hematology at GSK Mexico, stated that new targeted therapies and bispecific antibodies have changed the landscape of multiple myeloma treatment. · El Economista
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Thursday, September 3, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.